Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
30 April 2019 |
Main ID: |
EUCTR2010-024551-82-GB |
Date of registration:
|
14/03/2011 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
This a study using Atomoxetine in children with Attention Deficit Hyperactivity Disorder (ADHD) and a specific deletion in the 22qDS gene.
|
Scientific title:
|
OPEN LABEL TRIAL OF ATOMOXETINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN WITH 22q11.2 DELETION SYNDROME (22qDS) - Atomoxetine in 22qDS |
Date of first enrolment:
|
07/03/2012 |
Target sample size:
|
40 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-024551-82 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: yes Single blind: no Double blind: no Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: yes Other specify the comparator: immediate start vs delay of 8 weeks before initiation of treatment Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): yes
|
|
Countries of recruitment
|
United Kingdom
| | | | | | | |
Contacts
|
Name:
|
Professor Emily Simonoff
|
Address:
|
Department of Child and Adolescent Psychiatry
SE5 8AF
London
United Kingdom |
Telephone:
|
00440207848 5369 |
Email:
|
emily.simonoff@kcl.ac.uk |
Affiliation:
|
Institute of Psychiatry, King's College London |
|
Name:
|
Professor Emily Simonoff
|
Address:
|
Department of Child and Adolescent Psychiatry
SE5 8AF
London
United Kingdom |
Telephone:
|
00440207848 5369 |
Email:
|
emily.simonoff@kcl.ac.uk |
Affiliation:
|
Institute of Psychiatry, King's College London |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Children and adolescents of both genders, aged 7-17 years inclusive at the beginning of trial, with a genetically confirmed diagnosis of 22qDS.
2. Diagnosis of Attention Deficit Hyperactivity Disorder.
3. Access allowed to medical records
4. Participant is in a stable care situation.
5. Informed consent is obtained. Are the trial subjects under 18? yes Number of subjects for this age range: 40 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: 1. Children currently receiving atomoxetine will not be included. (Those who have received atomoxetine in the past regardless of response, may be included, provided they did not demonstrate frank intolerance, i.e. moderate to severe adverse effects at low doses).
2. A clear-cut history of intolerance to atomoxetine (defined as serious or moderate adverse events at very low doses eg 10mgs o.d)
3. Concomitant use of MAO inhibitor or narrow angle glaucoma (due to increased risk of mydriasis) represent absolute contradictions to the use of atomoxetine and constitute exclusion to the trial. MAOI use within the last 2 weeks or other drugs that affect brain monamine concentrations are also an exclusion
4. Severe limitation of mobility
5. Dementia or degenerative disorder
6. Poorly controlled or uncontrolled epilepsy
7. Presence of significant cardiovascular disease (Medical notes will be reviewed by a consulant paediatrician and further investigations undertaken, if necessary, to exclude any reason for inclusion).
8. Psychotic disorder or bipolar disorder.
9. Child has severe obsessive-compulsive disorder severe enough to require special treatment.
10. Child is being treated with neuroleptic or stimulant medication (children have to be off neuroleptic medication for at least 1 month and 1 week off stimulant medication prior to randomisation)
11. Child poses a significant risk of suicidal or homicidal behaviour
12. Children without a full-time school/college placement that is expected to continue for the next 4 months.
13. Another child the in family and/or household currently enrolled in this study
14. Children residing in a home without a telephone (land line or mobile)
15. Ongoing child protection concerns
16. For female participants, pregnancy or not wishing to have a pregnancy test at baseline, will be an exclusion criterion.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Attention Deficit Hyperactivity Disorder (ADHD) in children with 22qDS deletion syndrome
MedDRA version: 14.1
Level: LLT
Classification code 10064104
Term: ADHD
System Organ Class: 10037175 - Psychiatric disorders
|
Therapeutic area: Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04]
|
Intervention(s)
|
Trade Name: Strattera 10mg Product Name: Strattera 10mg Pharmaceutical Form: Capsule, hard CAS Number: 82248-59-7 Other descriptive name: Atomoxetine Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10-
Trade Name: Strattera 18mg Product Name: Strattera 18mg Pharmaceutical Form: Capsule, hard CAS Number: 82248-59-7 Other descriptive name: Atomoxetine Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 18-
Trade Name: Strattera 25mg Product Name: Straterra 25mg Pharmaceutical Form: Capsule, hard CAS Number: 82248-59-7 Other descriptive name: Atomoxetine Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25-
Trade Name: Strattera 40mg Product Name: Straterra 40mg Pharmaceutical Form: Capsule, hard CAS Number: 82248-59-7 Other descriptive name: Atomoxetine Hydrochloride Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-
Trade Name: Strattera 60mg Product Name: Straterra 60mg Pharmaceutical Form: Capsule, hard CAS Number: 82248-59-7 Other descriptive name: ATOMOXETINE HYDROCHLORIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 60-
Trade Name: Strattera 80mg Product Name: Straterra 80mg
|
Primary Outcome(s)
|
Main Objective: What is the efficacy of atomoxetine in reducing the symptoms of ADHD among children with 22qDS who also have ADHD.
|
Secondary Objective: What is the adverse effects profile associated with atomoxetine treatment amongst children with 22qDS and ADHD.
|
Primary end point(s): Reduction in symptoms of hyperactive behaviour (overactivity, poor concentration and impulsivity) as rated by parents and teachers on the ADHD index of the short version of the Conners scale (CRS-S; Conners, 1989). Baseline ratings will be compared to ratings taken during Week 16. The proportion of “responders” will be estimated using the following three definitions of a “responder”: i) At least a 30% decrease in symptoms in week 16 score compared to baseline score based on parent ratings on the ADHD index of the CRS-S ii) At least a 30% decrease in symptoms in week 16 score compared to baseline score based on teacher ratings on the ADHD index of the CRS-S iii) Where a child is classified as a responder on the basis of both parent and teacher ratings on the ADHD index of the CRS-S as defined above. Additionally, participants achieving at least 50% decrease in symptoms will be considered good responders.
|
Timepoint(s) of evaluation of this end point: 16 weeks
|
Secondary Outcome(s)
|
Secondary end point(s): Secondary outcome measures include: parent and teacher hyperactivity scale ratings on the Conners Rating Scales
Clinicians’ ratings of improvement in relation to symptoms and impairment as rated on the Clinical Global Impressions Scale at the end of the trial ("Clinical Global Impressions Scale," 1985))
Changes in other behaviours commonly seen in children with learning disabilities will be evaluated by parent and teacher ratings on the Aberrant Behavior Checklist (Aman, Singh, Stewart, & Field, 1985) at baseline and at week 16.
Adverse events will be primariy recorded using the 'Other Behaviors Questonnaire' at baseline, during tiration and weeks 8, 12, 16
|
Timepoint(s) of evaluation of this end point: 8 and 16 weeks
|
Secondary ID(s)
|
ATOM_22qDS/2011
|
Source(s) of Monetary Support
|
King's College London
|
NIHR Central Commissioning Facility
|
Ethics review
|
Status: Approved
Approval date:
Contact:
|
|